Pfizer Strikes Historic Deal To Cut U.S. Drug Prices; Offers Up to 85% Discounts on Medicines Through TrumpRx.gov Platform

Pfizer Inc. has reached a landmark agreement with the Trump Administration aimed at lowering prescription drug prices for U.S. patients while reinforcing America’s position as a global leader in biopharmaceutical innovation.

“We are proud to join President Trump at the White House to celebrate this landmark agreement that is a win for American patients, a win for American leadership, and a win for Pfizer. By working closely with the Administration, we are lowering costs for patients and enabling greater investment in the U.S. biopharmaceutical ecosystem by ending the days when American families alone carried the global burden of paying for innovation. This is about putting all patients first and ensuring America remains the world’s leading engine of medical breakthroughs,” said Albert Bourla, Chairman and Chief Executive Officer of Pfizer. 

As part of the agreement, Pfizer has committed to align U.S. medicine prices with those in other developed nations and will price newly launched drugs at parity with key markets. In addition, the company will participate in TrumpRx.gov, a direct purchasing platform that allows American patients to access Pfizer medicines at discounts averaging 50% and in some cases reaching 85%. The initiative will cover the majority of Pfizer’s primary care treatments and select specialty medicines.

Dr. Bourla continued, “We now have the certainty and stability we need on two critical fronts, tariffs and pricing, that have suppressed the industry’s valuations to historic lows. We've agreed to a three-year grace period during which time Pfizer products under a Section 232 investigation won't face tariffs, provided we further invest in manufacturing in the United States. Additionally, we've established a balanced global pricing approach that continues to recognize the value of innovation while ensuring prices in the U.S. and other developed countries are both reasonable and sustainable, maintaining the strength of the U.S. market alongside other developed nations.”

He also said, “This agreement allows us to invest even more boldly in the United States – fueling growth, creating jobs, and returning manufacturing home. Our U.S. workforce of 31,000 colleagues, supported by 13 manufacturing and distribution sites and 7 major R&D facilities, underscores Pfizer’s vital role in building a stronger American economy.

We are committed to channeling unprecedented resources with an additional $70 billion dedicated to U.S. research, development and capital projects in the next few years. This builds upon our more than $83 billion investment in American biotech innovation from 2018-2024, showing how we are strengthening our commitment at this pivotal moment by shaping the future of medicine with the pursuit of pioneering breakthroughs and ensuring the U.S. remains the global hub for medical progress and improving lives.”

With pricing measures in place, Pfizer plans to intensify its focus on advancing breakthrough therapies across key areas including oncology, obesity, vaccines, and inflammation and immunology—leveraging its scientific expertise, scale, and agility to deliver the next generation of cures.